Protagonist Therapeutics, Inc. (PTGX): Earnings News

PTGX – Reports Q4 EPS loss of $0.15 and revenue of $11.28M.

Key Facts Surrounding This News Item

  • PTGX had a POWR Rating of B (Buy) coming into today.
  • PTGX was 13.27% above its 10-Day Moving Average coming into today.
  • PTGX was 15.79% above its 20-Day Moving Average coming into today.
  • PTGX was 6.86% above its 50-Day Moving Average coming into today.
  • PTGX was 12.73% above its 100-Day Moving Average coming into today.
  • PTGX was 30.61% above its 200-Day Moving Average coming into today.
  • PTGX had returned -0.72% year-to-date leading up to today’s news, versus a +2.26% return from the benchmark S&P 500 during the same period.

More Info About Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded in 2006 and is based in Milpitas, California. View our full PTGX ticker page with ratings, news, and more.

PTGX at a Glance

PTGX Current POWR Rating™
Overall POWR Rating™
PTGX Current Price $6.83 2.29%
More PTGX Ratings, Data, and News

PTGX Price Reaction

The day of this event (Mar. 7, 2018)
PTGX Closing Price$20.89 1.16%
PTGX Volume89,500
10.67% from avg
Leading up to this event
PTGX 1-mo return15.49%
After this event
PTGX 1-day return2.08%
PTGX 3-day return1.38%
PTGX 5-day return1.18%

PTGX Price Chart

The Top Stocks For 2019

More Protagonist Therapeutics, Inc. (PTGX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All PTGX News
Page generated in 0.9685 seconds.